Lexeo Therapeutics Inc (LXEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,196 | -99,961 | -79,042 | -58,759 | -32,656 |
| Depreciation Amortization | 31 | 379 | 301 | 168 | 72 |
| Accounts payable and accrued liabilities | -1,596 | -1,561 | -1,761 | 13,507 | 5,143 |
| Other Working Capital | -4,207 | -9,515 | -7,116 | 5,389 | 6,730 |
| Other Operating Activity | 4,824 | 12,097 | 9,136 | -9,240 | -1,005 |
| Operating Cash Flow | $-21,144 | $-98,561 | $-78,482 | $-48,935 | $-21,716 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -35 | -397 | -397 | -108 | N/A |
| Purchase Of Investment | N/A | -195,382 | -55,366 | -55,366 | N/A |
| Sale Of Investment | 27,495 | 105,527 | 67,200 | 31,900 | 15,600 |
| Investing Cash Flow | $27,460 | $-90,252 | $11,437 | $-23,574 | $15,600 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -121 | -533 | -364 | -281 | -159 |
| Common Stock Issued | 2,598 | 234,078 | 80,304 | 80,169 | 170 |
| Other Financing Activity | -25 | -16,750 | -6,917 | -6,917 | 0 |
| Financing Cash Flow | $2,452 | $216,795 | $73,023 | $72,971 | $11 |
| Beginning Cash Position | 66,248 | 38,266 | 38,266 | 38,266 | 38,266 |
| End Cash Position | 75,016 | 66,248 | 44,244 | 38,728 | 32,161 |
| Net Cash Flow | $8,768 | $27,982 | $5,978 | $462 | $-6,105 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,144 | -98,561 | -78,482 | -48,935 | -21,716 |
| Capital Expenditure | -35 | -397 | -397 | -108 | N/A |
| Free Cash Flow | -21,179 | -98,958 | -78,879 | -49,043 | -21,716 |